Trials / Terminated
TerminatedNCT01596530
Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the activity of AZD8931 against placebo on the cell markers in cancer tumours
Detailed description
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for Treatment with trastuzumab as defined by IHC status
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug-AZD8931 | Active drug for biological activity |
| DRUG | Drug-Placebo | Placebo comparator for biological activity comparison |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-03-01
- Completion
- 2013-05-01
- First posted
- 2012-05-11
- Last updated
- 2012-12-17
Locations
7 sites across 3 countries: Germany, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01596530. Inclusion in this directory is not an endorsement.